Genovate Biotechnology Co., Ltd.

TPEX:4130 Stock Report

Market Cap: NT$2.3b

Genovate Biotechnology Valuation

Is 4130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4130 (NT$20.7) is trading below our estimate of fair value (NT$26.13)

Significantly Below Fair Value: 4130 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4130?

Key metric: As 4130 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4130. This is calculated by dividing 4130's market cap by their current earnings.
What is 4130's PE Ratio?
PE Ratio145.8x
EarningsNT$15.87m
Market CapNT$2.31b

Price to Earnings Ratio vs Peers

How does 4130's PE Ratio compare to its peers?

The above table shows the PE ratio for 4130 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.8x
6817 Winston Medical Supply
11.1xn/aNT$1.7b
8279 Syngen BiotechLtd
14.4xn/aNT$3.4b
1762 Chunghwa Chemical Synthesis & Biotech
26.2xn/aNT$2.6b
4747 Johnson Chemical Pharmaceutical Works
39.3xn/aNT$3.2b
4130 Genovate Biotechnology
145.8xn/aNT$2.3b

Price-To-Earnings vs Peers: 4130 is expensive based on its Price-To-Earnings Ratio (145.8x) compared to the peer average (22.8x).

Price to Earnings Ratio vs Industry

How does 4130's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4130 145.8xIndustry Avg. 21.7xNo. of Companies7PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4130 is expensive based on its Price-To-Earnings Ratio (145.8x) compared to the TW Pharmaceuticals industry average (21.7x).

Price to Earnings Ratio vs Fair Ratio

What is 4130's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4130 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio145.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4130's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genovate Biotechnology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.
Xiaowei HuangMasterlink Securities Corp.